Cellular and Molecular Dysregulations of Solid Tumors
A special issue of Cells (ISSN 2073-4409).
Deadline for manuscript submissions: closed (31 March 2024) | Viewed by 1020
Special Issue Editor
Interests: molecular oncology; immunotherapy; solid tumors
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Cancer continues to take a toll on global public health systems, accounting for an estimated 8.7 million deaths annually. In 2015, 17.5 million incident cases were diagnosed worldwide, and this is projected to spiral to 22.2 million by 2030.
Despite tremendous progress in reducing mortality rates from cancer and transformative shifts in therapeutic paradigms over the past few years, investigation of the molecular and cellular aspects of solid tumor remains an urgent priority.
Solid tumors commonly arise from genetic mutations in driver oncogenes and tumor suppressor genes that have profound consequences on cell differentiation, proliferation, survival, and genomic stability. During cancer progression, tumor cells alter normal developmental processes to orchestrate a supportive but overtly immunosuppressive tumor microenvironment (TME) comprised of immune cells, fibroblasts, and endothelial cells, often embedded within a robust extracellular matrix (ECM). Characterizing the complex composition of cellular and molecular aspects of solid tumors is fundamental for understanding tumor initiation, progression and metastasis. In this Special Issue, we invite investigators to contribute original research or review articles that highlight recent important advances in cellular and molecular dysregulations of solid tumors. Potential topics include but are not limited to the following:
- Genomic and proteomic characteristics of solid tumors
- Tumor microenvironment and its role in tumor development, growth, and metastasis
- Cancer stem cells and their roles in tumor development, drug resistance, and metastasis
- Dysregulation of signaling pathways and their role in promoting cancer and drug resistance
- Novel mechanisms underlying tumor development
Dr. Raheleh Roudi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- solid tumors
- signaling pathways
- genetic dysregulations
- cellular abnormalities
- cancer treatment
